Serum miR-16 as a potential biomarker for human cancer diagnosis: results from a large-scale population
- 34 Downloads
Cancer is a serious public health problem worldwide, and difficulty in early diagnosis has been the chief obstacle to improve the prognosis of patients. Recently, microRNAs (miRNAs) were widely studied to be potential biomarkers for cancer detection. miR-16 is a prevalent but sophisticated one. In the current study, we aimed to assess the diagnostic value of serum miR-16 for cancer detection.
A total of 1458 cancer patients, containing ten types of cancers, and 1457 non-cancer controls were recruited in this study. qRT-PCR was used for the amplification of miRNAs. In addition, a meta-analysis of reported studies was performed to confirm our findings systematically.
Consequently, miR-16 was down-regulated in ESCC, GCA and GNCA patients compared with NCs (all P < 0.001), while up-regulated in PDAC patients (P = 0.001), LAC, LSCC and EEC patients (all P < 0.001). But no significant differences were observed in CRC, EOC and TC patients when compared to NCs (P = 0.747, 0.235 and 0.268, respectively). The areas under the receiver operating characteristic (ROC) curve of miR-16 in GCA, ESCC, LAC, LSCC, GNCA, PDAC and EEC were 0.881, 0.780, 0.757, 0.693, 0.602, 0.614 and 0.681, respectively. Results of meta-analysis showed that miR-16 achieved an overall pooled sensitivity of 0.72, specificity of 0.79, and AUC of 0.85, suggesting that miR-16 was a promising biomarker in cancer detection.
We provided a comprehensive view of the diagnostic value of serum miR-16 in cancer diagnosis, and confirmed that circulating miR-16 could play an important role in cancer detection.
KeywordsCancer Circulation MicroRNA-16 Diagnosis Meta-analysis
We thank Ping Liu and Wei Zhu (Department of Oncology, the First Affiliated Hospital of Nanjing Medical University) for constructive suggestion.
HZB, CWJ and DYP performed experiments; HZB conducted the meta-analysis; GQ and SD reviewed eligible articles; WXH and MY provided the serum samples of patients and normal controls; HZB and ZX drafted the manuscript; ZX and HD designed the study, critically interpreted results; All authors read and approved the final manuscript.
Supported by grants: (1) Wuxi Health and Family Planning Commission Project; Grant number: Q201724. (2) Kunshan Social Development Science and Technology Project; Grant number: KS1643.
Compliance with ethical standards
Conflict of interest
All authors declare that they have no conflict of interest.
All the procedures were approved by the Ethics Committee of the First Affiliated Hospital of Nanjing Medical University and the Affiliated Hospital of Jiangnan University in compliance with the Declaration of Helsinki, and the written informed consent was obtained from each participant.
Informed consent was obtained from all individual participants included in the study.
- Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, Rassenti L, Kipps T, Negrini M, Bullrich F, Croce CM (2002) Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 99(24):15524–15529CrossRefGoogle Scholar
- Gao L, He SB, Li DC (2014) Effects of miR-16 plus CA19-9 detections on pancreatic cancer diagnostic performance. Clin Lab 60(1):73–77Google Scholar
- Johansen JS, Calatayud D, Albieri V, Schultz NA, Dehlendorff C, Werner J, Jensen BV, Pfeiffer P, Bojesen SE, Giese N, Nielsen KR, Nielsen SE, Yilmaz M, Hollander NH, Andersen KK (2016) The potential diagnostic value of serum microRNA signature in patients with pancreatic cancer. Int J Cancer 139(10):2312–2324CrossRefGoogle Scholar
- Li S, Zhang H, Wang X, Qu Y, Duan J, Liu R, Deng T, Ning T, Zhang L, Bai M, Zhou L, Wang X, Ge S, Ying G, Ba Y (2016) Direct targeting of HGF by miR-16 regulates proliferation and migration in gastric cancer. Tumour BiolGoogle Scholar
- Min S, Liang X, Zhang M, Zhang Y, Mei S, Liu J, Liu J, Su X, Cao S, Zhong X, Li Y, Sun J, Liu Q, Jiang X, Che Y, Yang R (2013) Multiple tumor-associated microRNAs modulate the survival and longevity of dendritic cells by targeting YWHAZ and Bcl2 signaling pathways. J Immunol 190(5):2437–2446CrossRefGoogle Scholar
- Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O’Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 105(30):10513–10518CrossRefGoogle Scholar
- Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA 65(2):87–108Google Scholar
- Wittmann J, Jack HM (2010) Serum microRNAs as powerful cancer biomarkers. Biochim Biophys Acta 1806(2):200–207Google Scholar
- Yamada A, Horimatsu T, Okugawa Y, Nishida N, Honjo H, Ida H, Kou T, Kusaka T, Sasaki Y, Yagi M, Higurashi T, Yukawa N, Amanuma Y, Kikuchi O, Muto M, Ueno Y, Nakajima A, Chiba T, Boland CR, Goel A (2015) Serum miR-21, miR-29a, and miR-125b are promising biomarkers for the early detection of colorectal neoplasia. Clin Cancer Res 21(18):4234–4242CrossRefGoogle Scholar